Showing results (1211-1220 of 1,261) with videos related to
Sort By:
Pageof 127
Scientific Reports|June 12, 2019
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.Scientific Reports|November 9, 2019
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic CancerGuoyun Zhu, Davide Foletti, Xiaohui Liu, et al.Plos One|July 11, 2015
Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC EfficacyMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.Cell Genomics|March 19, 2026
Functional chromatin signatures premark future lineage-specific enhancersJulian Pulecio, Zakieh Tayyebi, Dingyu Liu, et al.Bioconjugate Chemistry|February 3, 2015
Effect of attachment site on stability of cleavable antibody drug conjugatesMagdalena Dorywalska, Pavel Strop, Jody A Melton-Witt, et al.Annals of the Rheumatic Diseases|June 20, 2025
Influence of canstatin on fibroblast-driven hypervascularisation in rheumatoid arthritisCorinna Heck, Birgit Zimmermann-Geller, Sophie Haun, et al.Nature|February 10, 2012
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingHirokazu Matsushita, Matthew D Vesely, Daniel C Koboldt, et al.Journal of Molecular Biology|May 1, 2012
Generating bispecific human IgG1 and IgG2 antibodies from any antibody pairPavel Strop, Wei-Hsien Ho, Leila M Boustany, et al.Journal of Neuro-Oncology|January 12, 2013
A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countriesDaniel Satgé, Charles A Stiller, Stefan Rutkowski, et al.The Journal of Biological Chemistry|January 21, 2011
Structural basis for selective small molecule kinase inhibition of activated c-MetKeith W Rickert, Sangita B Patel, Timothy J Allison, et al.Pageof 127